2 stories mentioning SHE:300086Updated 43d ago
Every FINWIRES story that references SHE:300086, newest first.
China's drug regulator approved Honz Pharmaceutical's (SHE:300086) clinical trial for a pediatric indication for its Ceftazidime Tazobactam Sodium injection, according to a Tuesday filing with the Shenzhen bourse.The drug treats moderate to severe infections caused by beta-lactamase-producing bacteria.
Honz Pharmaceutical (SHE:300086) obtained drug registration for its carbocisteine granules from China's drug regulator, according to a Tuesday filing with the Shenzhen bourse.The drug is indicated for treating thick sputum and difficulty in expectoration caused by diseases such as bronchitis and bronchial asthma.The approval is valid for 24 months.Shares of the pharmaceutical company closed less than 1% higher Tuesday.
